ArticleMolecular and cellular biochemistry2026
Celastrol alleviates synovial inflammation and joint destruction in rheumatoid arthritis in association with Nrf2/HO-1/GPX4 pathway activation.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, oxidative imbalance, and progressive joint destruction. Celastrol (CEL), a bioactive triterpenoid derived from Tripterygium wilfordii, exhibits anti-inflammatory and antioxidant activities, but its mechanism of action in RA remains incompletely defined. This study investigated whether the Nrf2/HO-1/GPX4 pathway is involved in the protective effects of CEL in RA. Collagen-induced arthritis (CIA) rats were treated with CEL or methotrexate for 4 weeks. Arthritis severity, serum inflammatory cytokines, histopathological injury, oxidative stress, and pathway-related proteins were evaluated. In vitro, TNF-α-stimulated fibroblast-like synoviocytes (FLS) were used to assess proliferation, migration, invasion, apoptosis, inflammatory responses, and ROS/Fe²⁺ accumulation. tBHQ and Brusatol were used as pharmacological pathway-modulating probes in functional and rescue experiments. CEL significantly reduced paw swelling, arthritis scores, and serum IL-1β, IL-6, and TNF-α levels in CIA rats, and attenuated synovial hyperplasia, cartilage damage, collagen loss, and osteoclast activation. CEL also increased Nrf2, HO-1, and GPX4 expression while reducing ROS and Fe
Indexed as
Identifiers
42663877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.